Apple is pushing back against a U.S. trade tribunal's decision to block imports of certain Apple Watches in a patent dispute with medical technology company Masimo. The tech giant has appealed to the U.S. Court of Appeals for the Federal Circuit, challenging the basis of the ban. Apple argues that the International Trade Commission's ruling was flawed due to defective patent assessments and asserts that Masimo did not demonstrate sufficient investment in competing U.S. products to justify the import ban.
Masimo, a company specializing in medical monitoring technology, has accused Apple of poaching its employees and stealing pulse oximetry technology following discussions about potential collaboration. Apple integrated pulse oximetry into its Series 6 Apple Watches in 2020, a move that prompted the dispute with Masimo. The ITC sided with Masimo on December 26, leading to the prohibition of Apple's Series 9 and Ultra 2 smartwatches due to alleged patent infringement related to blood-oxygen level readings.
In response to the import ban, Apple obtained a temporary stay from the Federal Circuit, allowing it to resume sales of the affected watches. However, the ban was reinstated in January, prompting Apple to modify the watches by removing the pulse oximetry feature for the duration of the appeal process, which could extend for up to a year. Despite these changes, U.S. Customs and Border Protection determined that the redesigned watches did not violate Masimo's patents and were exempt from the ban, as they lacked pulse oximetry functionality.
Apple's argument to the Federal Circuit revolves around the contention that Masimo's wearable technology covered by the patents was merely theoretical when the complaint was filed in 2021, making the ban unjustifiable. Additionally, Apple asserts that Masimo's patents are invalid and that its watches do not infringe upon them. The dispute underscores the ongoing legal battles in the tech industry over intellectual property rights and highlights the complexities of patent enforcement in the global marketplace.